IC-SARI
Immuno-Compromised Severe Acute Respiratory Infection (IC-SARI) project.
An observational study into the causes of severe acute respiratory infections among people with immunocompromising conditions.
What is this study about?
IC-SARI is part of the STRIVE observational master study protocol: An International Observational Study of Adults with Acute Infection (STRIDE (STRIVE 002))
This international observational study will collect longitudinal data and biological samples in hospitalised adults with severe acute respiratory infections among immunocompromised adults, in an international setting.
This project will enroll adults with an immunocompromising (IC) condition admitted to the hospital with a severe acute respiratory infection (SARI).
Relatively little is known about the causes of severe acute respiratory infections among immunocompromised people and whether the causes and/or clinical outcomes vary by different immunocompromising conditions or global regions. A global assessment is critical for understanding regional variation in immunocompromising conditions, pathogens causing severe disease in immunocompromised patients, and clinical outcomes.
There is a need for rigorous, prospective assessments of immunocompromised patients with severe respiratory infections to generate data that can be used to design new interventions and clinical trials, which will be necessary to curb the severe morbidity and mortality from this disease.
Network: An international observational STudy of Respiratory infections & Infectious disease Emergencies (STRIDE).
Type of study
Observational study
Who is funding the study?
The study is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA).
When is it taking place?
The study opened in 2025 and will run for at least 3 years.
Where is it taking place?
The study is being conducted at sites in the following: Africa, America (North and South), Asia, Australia, the European Union and the UK. Sites affiliated with the MRC CTU at UCL are located in the UK, Greece, Uganda, and Zimbabwe.
Who is included?
The project will enroll adults aged 18 years or older admitted to hospital with a moderate-to-severe immunocompromising condition hospitalized for SARI.